Financial Report: Merck 3Q11

Merck 3Q11
 

3Q Revenues: $12.0 billion (+8%)
 

3Q Earnings: $1.7 billion (earnings were $342.0 million 3Q10) 
 

YTD Revenues: $35.8 billion (+5%)
 

YTD Earnings: $4.8 billion (earnings were $1.5 billion YTD10)
 

Comments: Sales growth, including 5% from foreign exchange, was driven by pharmaceutical and animal health sales. Januvia sales were $846.0 million in the quarter (+41%). Gardasil sales were $445.0 million (+41%). Singulair sales were $1.3 billion (+10%). Janumet sales were $350.0 million (+4%). Isentress sales were $343.0 million (+23%). Remicade sales were down 15% in the quarter to $561.0 million, due to the transfer of marketing rights to Johnson & Johnson in Canada, Central and South America, the Middle East, Africa and Asia Pacific. Animal Health sales totaled $826 million in the quarter, up 20%. 2010 results include acquisition-related costs and restructuring costs.